Integrated study of Quercetin as a potent SARS-CoV-2 RdRp inhibitor: Binding interactions, MD simulations, and In vitro assays
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0312866 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Ahmed M Metwaly und 5 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacognosy and Medicinal Plants Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt. Hauptthemen laut MEDLINE: Quercetin, SARS-CoV-2, Antiviral Agents, Molecular Dynamics Simulation. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Princess Nourah Bint Abdulrahman University.
Abstract (Originalsprache)
To find an effective inhibitor for SARS-CoV-2, Quercetin’s chemical structure was compared to nine ligands associated with nine key SARS-CoV-2 proteins. It was found that Quercetin closely resembles Remdesivir, the co-crystallized ligand of RNA-dependent RNA polymerase (RdRp). This similarity was confirmed through flexible alignment experiments and molecular docking studies, which showed that both Quercetin and Remdesivir bind similarly to the active site of RdRp. Molecular dynamics (MD) simulations over a 200 ns trajectory, analyzing various factors like RMSD, RG, RMSF, SASA, and hydrogen bonding were conducted. These simulations gave detailed insights into the binding interactions of Quercetin with RdRp compared to Remdesivir. Further analyses, including MM-GBSA, Protein-Ligand Interaction Fingerprints (ProLIF) and Profile PLIP studies, confirmed the stability of Quercetin’s binding. Principal component analysis of trajectories (PCAT) provided insights into the coordinated movements within the systems studied. In vitro assays showed that Quercetin is highly effective in inhibiting RdRp, with an IC 50 of 122.1 ±5.46 nM, which is better than Remdesivir’s IC 50 of 21.62 ±2.81 μM. Moreover, Quercetin showed greater efficacy against SARS-CoV-2 In vitro , with an IC 50 of 1.149 μg/ml compared to Remdesivir’s 9.54 μg/ml. The selectivity index (SI) values highlighted Quercetin’s safety margin (SI: 791) over Remdesivir (SI: 6). In conclusion, our comprehensive study suggests that Quercetin is a promising candidate for further research as an inhibitor of SARS-CoV-2 RdRp, providing valuable insights for developing an effective anti-COVID-19 treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Pharmacognosy and Medicinal Plants Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt.
- Protein Research Department, Genetic Engineering and Biotechnology Research Institute (GEBRI), City of Scientific Research and Technological Applications (SRTA-City), New Borg El-Arab City, Alexandria, Egypt.
- Pharmaceutical and Fermentation Industries Development Centre (PFIDC), City of Scientific Research and Technological Applications (SRTA-City), New Borg Al-Arab, Alexandria, Egypt.
- Pharos University in Alexandria, Alexandria, Egypt.
- Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia.
- Biophysics Department, Faculty of Science, Cairo University, Giza, Egypt.
ORCID-Profile: Ahmed M Metwaly, Aisha A Alsfouk
Förderung
- Princess Nourah Bint Abdulrahman University
Zitieren
APA
Metwaly, A. M., El-Fakharany, E. M., Alsfouk, A. A., Ibrahim, I. M., Elkaeed, E. B., & Eissa, I. H. (2024). Integrated study of Quercetin as a potent SARS-CoV-2 RdRp inhibitor: Binding interactions, MD simulations, and In vitro assays. PLOS ONE. https://doi.org/10.1371/journal.pone.0312866
Vancouver
Metwaly AM, El-Fakharany EM, Alsfouk AA, Ibrahim IM, Elkaeed EB, Eissa IH. Integrated study of Quercetin as a potent SARS-CoV-2 RdRp inhibitor: Binding interactions, MD simulations, and In vitro assays. PLOS ONE. 2024. doi:10.1371/journal.pone.0312866
BibTeX
@article{Metwaly2024,
author = {Metwaly, Ahmed M and El-Fakharany, Esmail M and Alsfouk, Aisha A and Ibrahim, Ibrahim M and Elkaeed, Eslam B and Eissa, Ibrahim H},
title = {Integrated study of Quercetin as a potent SARS-CoV-2 RdRp inhibitor: Binding interactions, MD simulations, and In vitro assays},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0312866}
}
EUVIMED